New sleeping pill poised to hit US markets
An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.
Medications
May 21, 2013 |
4.2 / 5 (5) |
0
Fecal microbiota tx feasible for recurrent C. difficile in HIV
(HealthDay)—For HIV-infected individuals with recurrent Clostridium difficile infection, fecal microbiota therapy is feasible, according to a letter published in the May 21 issue of the Annals of Intern ...
HIV & AIDS
21 hours ago |
not rated yet |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
21 hours ago |
not rated yet |
0
FDA has safety concerns on Merck insomnia drug
Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.
Medications
May 20, 2013 |
not rated yet |
0
Drugmakers, health groups bring poor girls vaccine
Two multinational drugmakers are teaming up with top global health groups to protect millions of girls in the world's poorest countries from deadly cervical cancer.
Medications
May 09, 2013 |
not rated yet |
0
Genetic variant may explain weight loss post-RYGB surgery
(HealthDay)—A genetic variant associated with weight loss after Roux-en-Y gastric bypass (RYGB) surgery has been identified, according to a study published in the May 2 issue of the American Journal of ...
Genetics
May 07, 2013 |
not rated yet |
0
Higher prices for MS drug help drug firm Merck
(AP)—Higher prices for its multiple sclerosis drug Rebif helped German pharmaceutical and high-tech materials company Merck KGaA post a 54 percent rise in first-quarter profit.
Other
May 14, 2013 |
not rated yet |
0
Merck says FDA reviewing its ragweed allergy therapy
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...
Medications
May 08, 2013 |
not rated yet |
0
Generic competition cuts Merck's Q1 sales, profit
Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.
Medications
May 01, 2013 |
not rated yet |
0
